story of the week
Bevacizumab With or Without Erlotinib as Maintenance Therapy for Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bevacizumab With or Without Erlotinib as Maintenance Therapy in Patients With Metastatic Colorectal Cancer (GERCOR DREAM; OPTIMOX3): A Randomised, Open-Label, Phase 3 Trial
Lancet Oncol 2015 Oct 13;[EPub Ahead of Print], C Tournigand, B Chibaudel, B Samson, W Scheithauer, D Vernerey, P Mésange, G Lledo, F Viret, JF Ramée, N Tubiana-Mathieu, J Dauba, O Dupuis, Y Rinaldi, M Mabro, N Aucoin, J Latreille, F Bonnetain, C Louvet, AK Larsen, T André, A de GramontFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.